Myasthenia Gravis

MG is an autoimmune disorder characterized by antibodies targeting the postsynaptic acetylcholine receptor or associated proteins at the neuromuscular junction. Clinical features include fluctuating skeletal muscle weakness, ptosis, diplopia, and dysphagia. Pathophysiology involves impaired neuromuscular transmission due to antibody-mediated receptor loss. Diagnosis relies on serology, electrophysiology, and response to acetylcholinesterase inhibitors. Management includes acetylcholinesterase inhibitors, immunosuppressants, thymectomy, and supportive care; prognosis is generally favorable with treatment.